NCT07590635Recruiting
eCardiacRehab - a Hybrid Patient-Centered eHealth Programme
eCardiacRehab - a Randomized Controlled Trial on a Hybrid Home-Based Patient-Centered eHealth Programme With Tailored Solutions
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all. eCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 21 May 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07590635
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 21 May 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Awaits percutaneous coronary intervention or coronary artery bypass graft surgery
Other illness
- Patients with cognitive impairment that may interfere with the ability to comply with the study protocol
- Severe arrhythmias
- Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel
Other
- Severe aortic stenosis
- Expected lifetime less than one year as determined by study personnel
- Otherwise clinically unstable
- Not fully revascularized
Who the study is looking for
- Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number
- With coronary artery disease after percutaneous coronary intervention
- Living at home
- Have internet available
- Provide signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.